The US Food and Drug Administration issued the alert and the laboratory that produces the drug under the Zantac brand announced that it will study the situation thoroughly.
Ranitidine, one of the most common drugs in the treatment of gastritis, ulcers and heartburn and that in many countries is sold without a medical formula, will be temporarily withdrawn from the market by the Novartis laboratory, which manufactures it under the Zantac brand. The decision was made after the United States drug and food agency, the FDA, issued an alert about it.
The FDA, through a statement, announced that it found nitrosodimethylamine (NDMA), considered a probably carcinogenic substance, present in this drug. In a statement, the pharmaceutical laboratory explained that for the time being “all medications containing ranitidine will cease to be distributed until it is clear.”
NDMA is a well-known environmental pollutant and is found in water and food, including meats, dairy products and vegetables.
“The FDA is not asking people to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their healthcare professional about other treatment options,” the agency explained. in your statement.
The agency’s recommendation is that people taking over-the-counter ranitidine may consider using other over-the-counter medications approved for their condition.